Moss R B, Giermakowska W K, Savary J R, Theofan G, Daigle A E, Richieri S P, Jensen F C, Carlo D J
The Immune Response Corporation, Carlsbad, California 92008, USA.
AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S167-75.
The ability to recognize HIV antigens is lost early in HIV-1 infection. Individuals with nonprogressive HIV disease have been observed to mount strong immune responses against the virus and have become a paradigm to emulate with immune-based therapies. Highly active antiviral drug therapy (HAART) has now become the standard of care for HIV-1-infected individuals. Because HIV-specific anergy occurs early in HIV infection, HAART initiated after primary infection may not reconstitute HIV-specific immune function. We have been investigating the effects of an immune-based therapy, called REMUNE, in HIV-1-seropositive individuals. REMUNE has been observed to stimulate HIV-1-specific immune function measured by delayed-type hypersensitivity, lymphocyte proliferation, Th1 cytokine, and beta-chemokine production. Multiple Phase II studies and a Phase III clinical end-point study are ongoing in thousands of seropositive individuals in order to test the clinical utility of REMUNE. The clinical testing of REMUNE and other promising immune-based therapies may provide additional treatment modalities useful in the chronic management of HIV-1.
在HIV-1感染早期，识别HIV抗原的能力就会丧失。据观察，患有非进展性HIV疾病的个体能够对该病毒产生强烈的免疫反应，并且已成为基于免疫疗法效仿的范例。高效抗逆转录病毒药物疗法（HAART）现已成为HIV-1感染者的标准治疗方法。由于HIV特异性无反应性在HIV感染早期就会出现，初次感染后开始的HAART可能无法恢复HIV特异性免疫功能。我们一直在研究一种名为REMUNE的基于免疫的疗法对HIV-1血清阳性个体的影响。据观察，REMUNE可通过迟发型超敏反应、淋巴细胞增殖、Th1细胞因子和β趋化因子产生来刺激HIV-1特异性免疫功能。目前正在数千名血清阳性个体中进行多项II期研究和一项III期临床终点研究，以测试REMUNE的临床效用。REMUNE和其他有前景的基于免疫的疗法的临床试验可能会提供有助于HIV-1慢性管理的额外治疗方式。
